FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer

Stock Information for FibroGen Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About FibroGen Inc

FibroGen Announces 1-for-25 Reverse Stock Split
FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors
FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update
FibroGen to Report First Quarter 2025 Financial Results
FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference
FibroGen Announces Publication of Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer in the Journal of Clinical Oncology
FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results
FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.